Compare DexCom, Inc. (DXCM) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MSCI Australia ETF — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while iShares MSCI Australia ETF trades at $28.27 (market cap $1.17B). The key difference: DexCom, Inc. is far larger — about 27.2× iShares MSCI Australia ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares MSCI Australia ETF for 63 Days on average.
| DXCM | EWA | |
|---|---|---|
Market Cap | $31.86B | $1.17B |
Volume | 3,607,070 | 2,121,231 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $30.43 |
52-Week Low | $54.84 | $24.95 |
Typical Hold Time | 62 Days | 63 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
EWA, the iShares MSCI Australia ETF, trades at $28.23, down 1.12% amid broader Australian market weakness. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent institutional activity includes Squarepoint Ops reducing its stake by 91.2% while other firms like Empowered Funds and Cetera Investment Advisers increased positions. The ETF serves as a commodity proxy, benefiting from Australia's export-driven economy.
The outlook remains cautious with technical weakness and mixed institutional sentiment. Upside potential exists if commodity demand drives Australian equities higher, but near-term risks include persistent inflation concerns and tight monetary policy. The Seeking Alpha buy rating targeting $34.83 suggests over 20% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
